RCUS Stock Analysis: Buy, Sell, or Hold?
RCUS - Arcus Biosciences, Inc.
$21.04
-0.75 (-3.44%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 24, 2026
24d
Get Alerted When RCUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RCUS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RCUS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RCUS is currently trading at $21.04, which is considered oversold relative to its 30-day fair value range of $21.59 to $23.37.
Technical Outlook: Technically, RCUS is in a strong uptrend. The price is currently testing key support at $20.70. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: RCUS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $33.00 (+51.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RCUS is in a strong uptrend. The price is currently testing key support at $20.70. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: RCUS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $33.00 (+51.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$21.59 -
$23.37
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 51.4% below Wall St target ($33.00)
Fair Price Analysis
30-Day Fair Range
$21.59 -
$23.37
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$2.18
(10.4%)
Support & Resistance Levels
Support Level
$20.70
Resistance Level
$23.78
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-5.66
Wall Street Target
$33.00
(+51.4%)
Revenue Growth (YoY)
-45.8%
Profit Margin
-142.1%
Last updated: January 30, 2026 5:40 PM ET
Data refreshes hourly during market hours. Next update: 6:40 PM
Data refreshes hourly during market hours. Next update: 6:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RCUS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Jennifer Jarrett
SELL
37792 shares
2025-10-08
Jennifer Jarrett
SELL
12500 shares
2025-10-06
Alexander Azoy
SELL
2831 shares
2025-09-29
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 59 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$141 | 59 HOLD |
Advanced RCUS Option Strategies
Professional options setups generated by AI based on today's RCUS price and gamma walls.
